BlackRock, Inc. Reports New 10.1% Passive Stake in Keros Therapeutics, Inc. (KROS)

On April 7, 2026, BlackRock, Inc. filed a Schedule 13G with the SEC, disclosing a significant new ownership stake in Keros Therapeutics, Inc. (KROS). As of the event date on March 31, 2026, BlackRock reported beneficial ownership of 1,990,842 shares of common stock, representing a 10.1% ownership interest in the company. This filing marks a substantial increase from a previously reported 0.0% position, establishing BlackRock as a major institutional shareholder. The filing indicates that BlackRock holds sole voting power over 1,960,306 shares and sole dispositive power over the full 1,990,842 shares. The acquisition was made in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiaries under the BlackRock, Inc. parent holding company are identified as the entities through which these shares are held. This passive investment reflects a high level of institutional interest in the biotechnology firm.